Autres langues Halozyme Therapeutics, Inc.

Actions

HALO

US40637H1095

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
38,57 ^USD	+0,29%		-0,18%	+4,36%

25/04	Halozyme Therapeutics, Inc. annonce l'élection de Mahesh Krishnan, M.D., à son conseil d'administration	CI
18/04	Un initié de Halozyme Therapeutics a vendu des actions pour une valeur de 768 390 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mahesh Krishnan Elected to Halozyme's Board of Directors	25/04
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	25/04
Halozyme to Report First Quarter 2024 Financial and Operating Results	23/04
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	18/04
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	13/03
Halozyme to Participate in Upcoming Investor Conferences	27/02
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	21/02
Halozyme Therapeutics: Q4 Earnings Snapshot	20/02
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	20/02
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	20/02
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	20/02
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20/02
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	20/02
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	20/02
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	20/02
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	08/02
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	01/02
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	30/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Halozyme Therapeutics, Inc.

Actions

HALO

US40637H1095

Autres langues

Filtres